These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22512630)

  • 1. JAK2 inhibition in murine systemic lupus erythematosus.
    Tagoe C; Putterman C
    Immunotherapy; 2012 Apr; 4(4):369-72. PubMed ID: 22512630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
    Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
    Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
    J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus.
    Lech M; Kantner C; Kulkarni OP; Ryu M; Vlasova E; Heesemann J; Anz D; Endres S; Kobayashi KS; Flavell RA; Martin J; Anders HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2207-17. PubMed ID: 21875872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice.
    Starke C; Frey S; Wellmann U; Urbonaviciute V; Herrmann M; Amann K; Schett G; Winkler T; Voll RE
    Eur J Immunol; 2011 Jul; 41(7):2107-12. PubMed ID: 21484784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
    Early GS; Zhao W; Burns CM
    J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
    Takasaki Y
    Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice.
    Kyttaris VC; Kampagianni O; Tsokos GC
    Biomed Res Int; 2013; 2013():861028. PubMed ID: 23841097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE
    Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
    Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK
    Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [B-lymphocytes as effectors and regulators in systemic lupus erythematosus].
    Winkler TH
    Z Rheumatol; 2014 May; 73(4):360-2. PubMed ID: 24722870
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
    Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental use of murine lupus models.
    Peng SL
    Methods Mol Med; 2004; 102():227-72. PubMed ID: 15286389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice.
    Wang S; Yang N; Zhang L; Huang B; Tan H; Liang Y; Li Y; Yu X
    Lupus; 2010 Sep; 19(10):1171-80. PubMed ID: 20501525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
    Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.